New basic patent has been granted for MP1032
Zurich, March 29, 2016. MetrioPharm AG announces that a basic patent has been granted on its lead compound MP1032 in two additional countries. This expands the list of countries in which MP1032 is exclusively protected from Europe, the USA, Australia, and New Zealand, to Israel and China.
The Israeli Patent No. 221680 was effectively granted on December 25, 2015. The Chinese patent No. CN102971300B was issued just recently, on March 02, 2016.
"Especially the Chinese patent should be considered a huge success," says the President of the Board Dr. Wolfgang Brysch.
The Chinese Patent Office is known to have very high demands. It is particularly reserved towards innovative patents in the pharmaceutical sector. Due to this success, a divisional application on selected therapeutic indications, targeted in MetrioPharm's development program, was filed in China.
"This is a crucial step towards a successful entry into the highly dynamic pharmaceutical market in China," according to Dr. Wolfgang Brysch.
MetrioPharm's proprietary drug candidate MP1032 is a novel synthetic small-molecule drug with strong anti-inflammatory properties and an excellent toxicity profile in pre-clinical studies. MP1032 belongs to a new class of macrophage-modulatory drugs that act on the innate immune system. MP1032 targets the molecular activation mechanisms of inflammatory macrophages. These cells drive the inflammation, pain and tissue damage in a wide range of inflammatory and auto-immune diseases such as psoriasis, rheumatoid arthritis, musculo-skeletal injuries and multiple sclerosis.
MetrioPharm is a clinical-stage drug development company with legal base in Zurich and an R&D location in Berlin. The company develops a breakthrough class of new anti-inflammatory and immune-modulating drugs against chronic inflammatory and auto-immune diseases.